Market Closed -
Deutsche Boerse AG
06:59:01 28/06/2024 pm IST
|
5-day change
|
1st Jan Change
|
0.172
EUR
|
0.00%
|
|
-6.52%
|
-76.44%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
64.81
|
26.2
|
14.92
|
6.199
|
-
|
-
|
Enterprise Value (EV)
2 |
50.99
|
18.79
|
14.92
|
5.599
|
5.699
|
4.899
|
P/E ratio
|
-5.29
x
|
-3.42
x
|
-
|
-1.51
x
|
50.5
x
|
7.48
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
331
x
|
1,092
x
|
324
x
|
62
x
|
12.4
x
|
5.17
x
|
EV / Revenue
|
261
x
|
783
x
|
324
x
|
56
x
|
11.4
x
|
4.08
x
|
EV / EBITDA
|
-9.46
x
|
-2.75
x
|
-2.88
x
|
-1.56
x
|
-2.28
x
|
-2.58
x
|
EV / FCF
|
-5.43
x
|
-3.17
x
|
-
|
-1.56
x
|
-
|
5.44
x
|
FCF Yield
|
-18.4%
|
-31.6%
|
-
|
-64.3%
|
-
|
18.4%
|
Price to Book
|
3.12
x
|
2.05
x
|
-
|
1.04
x
|
0.99
x
|
0.85
x
|
Nbr of stocks (in thousands)
|
25,481
|
25,486
|
25,486
|
30,659
|
-
|
-
|
Reference price
3 |
1.880
|
0.8500
|
0.4600
|
0.1600
|
0.1600
|
0.1600
|
Announcement Date
|
28/03/22
|
20/02/23
|
04/04/24
|
-
|
-
|
-
|
1GBP in Million2USD in Million3GBP Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
0.1956
|
0.024
|
0.046
|
0.1
|
0.5
|
1.2
|
EBITDA
1 |
-
|
-5.39
|
-6.84
|
-5.19
|
-3.6
|
-2.5
|
-1.9
|
EBIT
1 |
-
|
-5.714
|
-6.555
|
-
|
-3.8
|
-2.7
|
-2.1
|
Operating Margin
|
-
|
-2,921.7%
|
-27,312.5%
|
-
|
-3,800%
|
-540%
|
-175%
|
Earnings before Tax (EBT)
1 |
-
|
-7.428
|
-7.602
|
-
|
-3.9
|
0.1
|
0.8
|
Net income
1 |
-4.839
|
-7.444
|
-7.606
|
-
|
-3.9
|
0.1
|
0.8
|
Net margin
|
-
|
-3,806.41%
|
-31,691.67%
|
-
|
-3,900%
|
20%
|
66.67%
|
EPS
2 |
-0.0412
|
-0.3556
|
-0.2484
|
-
|
-0.1061
|
0.003170
|
0.0214
|
Free Cash Flow
1 |
-
|
-9.386
|
-5.93
|
-
|
-3.6
|
-
|
0.9
|
FCF margin
|
-
|
-4,799.43%
|
-24,708.33%
|
-
|
-3,600%
|
-
|
75%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
112.5%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
13/07/21
|
28/03/22
|
20/02/23
|
04/04/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
13.8
|
7.41
|
-
|
0.6
|
0.5
|
1.3
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-9.39
|
-5.93
|
-
|
-3.6
|
-
|
0.9
|
ROE (net income / shareholders' equity)
|
-
|
-31.5%
|
-45.7%
|
-51.4%
|
-66%
|
1.7%
|
11.4%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
0.6000
|
0.4100
|
-
|
0.1500
|
0.1600
|
0.1900
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
1.85
|
0.09
|
-
|
0.1
|
0.1
|
0.1
|
Capex / Sales
|
-
|
944.61%
|
354.17%
|
-
|
100%
|
20%
|
8.33%
|
Announcement Date
|
13/07/21
|
28/03/22
|
20/02/23
|
04/04/24
|
-
|
-
|
-
|
Last Close Price
0.16
GBP Average target price
2.2
GBP Spread / Average Target +1,275.00% Consensus |
1st Jan change
|
Capi.
|
---|
| -42.89% | 7.8B | | +6.77% | 3.53B | | -1.35% | 2.24B | | -27.06% | 1.84B | | -21.23% | 1.66B | | +9.31% | 951M | | +29.42% | 811M | | -12.66% | 670M | | -26.12% | 533M |
Bio Diagnostics & Testing
|